On December 4, Beijing QS Medical Technology Co., Ltd. (hereinafter referred to as "Quinovare") and Aim Vaccine Co., Ltd. (hereinafter referred to as "Aim Vaccine Group") signed a strategic cooperation agreement in the Beijing Economic and Technological Development Zone.
The strategic cooperation agreement was signed by Mr. Zhang Yuxin, founder, chairman and CEO of Quinovare, and Mr. Zhou Yan, founder, chairman of the board and CEO of Aim Vaccine Group, and was witnessed by the relevant person in charge of the biotechnology and big health industry special class of Beijing Economic and Technological Development Zone the process of signing the contract between the two parties. The signing of the agreement marks the official launch of the multi-field and all-round cooperation between Quinovare and Aim Vaccine Group. This is not only the complementary advantages of the two leading companies in their respective fields, but also another new highlight for Beijing Economic Development Zone to create a global pharmaceutical and health industry brand with Yizhuang characteristics.
Aim Vaccine Group is a large-scale private vaccine group with a full industry chain in China. Its business covers the entire industry value chain from research and development to manufacturing to commercialization. In 2020, it obtained a batch release volume of approximately 60 million doses and achieved delivery to 31 provinces in China. Autonomous regions and municipalities sell vaccine products. Currently, the company has 8 commercial vaccines targeting 6 disease areas, and 22 innovative vaccines under development targeting 13 disease areas. The products in production and research cover all the top ten vaccine products in the world (based on global sales in 2020).
Quinovare is the world's leading company in needle-free drug delivery systems. It focuses on the development of needle-free drug delivery technology and can accurately achieve intradermal, subcutaneous and intramuscular drug delivery. It has obtained registration approval documents from NMPA for needle-free injection of insulin, growth hormone, and incretin will be approved soon. Quinovare has the world-class automated production line for needle-free injection drug delivery devices. The production system has passed ISO13485, and has dozens of domestic and foreign patents (including 10 PCT international patents). It is authorized a national high-tech enterprise and a specialized- tech medium-sized enterprise in Beijing.
Finally, the exchange ended happily and enthusiastically. The two parties reached a number of cooperation consensuses.
The Institute of Materia Medica of the Chinese Academy of Medical Sciences will cooperate with Quinovare in the field of needle-free drug delivery and jointly promote the application of needle-free drug delivery technology in the Chinese medical market application!
Chairman of Aim Vaccine Group Zhou Yan pointed out at the signing ceremony that the development of the industry and the development of the market require proactive cooperation, the courage to try and the ability to think across borders. The cooperation between the two parties is in line with this concept.Mr. Zhang Fan, Vice President and Chief Research Officer of Aim Vaccine Group, believes that both parties are leaders in their respective fields. They are both companies integrating research, production and sales, and have a good foundation for cooperation. The safety of needle-free drug delivery technology can effectively solve or reduce local and even systemic adverse reactions. The combination of vaccines and needle-free drug delivery products can effectively promote technological innovation in the industry.
Mr. Zhang Yuxin, Chairman of Quinovare Medical, is full of expectations for the cooperation between the two parties. He believes that the cooperation between Aim Vaccine Group and Quinovare will achieve the superposition of advantages of both parties and promote technological innovation in the industry, thereby promoting the progress and development of the industry.
Applying advanced needle-free drug delivery technology to vaccination is a trend in developed countries abroad, but it is still a blank field in China. Needle-free drug delivery technology is a more convenient and safer way to administer drugs, improving comfort and acceptance among vaccinated populations. Through this new type of combined drug and device products, differentiated competitive advantages will be formed, the profitability of the company will be improved, and the healthy development of the company will be promoted.
We believe that the cooperation between Aim Vaccine Group and Quinovare Medical will usher in a new era of vaccine delivery, improving efficacy and patient experience through technological innovation. In addition, the cooperation between the two parties can share resources and experience in their respective fields, improve the accessibility and affordability of vaccines, and contribute to the development of global public health by promoting technological innovation and industrial upgrading!
Post time: Dec-11-2023